Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring HERCEPTIN, Carboplatin, Paclitaxel, Relapse
Eligibility Criteria
Inclusion Criteria: 18 years or older; patients with histologically proven diagnosis of ovarian cancer. Patients with metastatic disease and an overexpression of HER2 (as determined by immunochemistry) Patients who have progressed while receiving treatment, or within 6 months after completion of treatment. Patients must have received carboplatin and paclitaxel. Patients who have received at minimum one line of chemotherapy 3 weeks minimum since last treatment with chemotherapy must have elapsed Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 > 1.25 x upper limit of normal (ULN) Patients must have ECOG of 2 or less Left ventricular ejection fraction (LVEF) of 50% or better Patients have given their signed and verbal consent Exclusion Criteria: Previous treatment with Herceptin or similar products affected growth factors (eg: Iressa) Another experimental treatment in the previous 30 days No overexpression of HER2 receptors Patients having received high-dose chemotherapy or stem-cell interventions Other cancers within the last 5 years Patients with dyspnea at rest or requiring oxygen therapy
Sites / Locations
- Hopital Hotel-Dieu